Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug safety under the microscope for Tough-to-Treat blood cancer

NCT ID NCT04872621

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study monitored the safety of the drug Calquence (acalabrutinib) in a real-world setting after it was approved for use. It involved 104 patients whose chronic lymphocytic leukemia had returned or did not respond to prior treatment. The main goal was to track the frequency and types of side effects experienced by patients using the drug in regular medical practice.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Aichi, D8224C00001, Japan

  • Research Site

    Aichi, Japan

  • Research Site

    Akita, Japan

  • Research Site

    Aomori, D8224C00001, Japan

  • Research Site

    Chiba, D8224C00001, Japan

  • Research Site

    Chiba, Japan

  • Research Site

    Fukui, Japan

  • Research Site

    Fukuoka, D8224C00001, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Gifu, Japan

  • Research Site

    Gunma, D8224C00001, Japan

  • Research Site

    Gunma, Japan

  • Research Site

    Hiroshima, D8224C00001, Japan

  • Research Site

    Hiroshima, Japan

  • Research Site

    Hokkaido, D8224C00001, Japan

  • Research Site

    Hokkaido, Japan

  • Research Site

    Hyōgo, D8224C00001, Japan

  • Research Site

    Hyōgo, Japan

  • Research Site

    Ibaraki, D8224C00001, Japan

  • Research Site

    Ibaraki, Japan

  • Research Site

    Ishikawa, Japan

  • Research Site

    Kagoshima, D8224C00001, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Kanagawa, D8224C00001, Japan

  • Research Site

    Kanagawa, Japan

  • Research Site

    Kochi, Japan

  • Research Site

    Kumamoto, Japan

  • Research Site

    Kyoto, D8224C00001, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Mie, Japan

  • Research Site

    Miyagi, D8224C00001, Japan

  • Research Site

    Miyagi, Japan

  • Research Site

    Miyazaki, Japan

  • Research Site

    Nagano, Japan

  • Research Site

    Nagasaki, D8224C00001, Japan

  • Research Site

    Nagasaki, Japan

  • Research Site

    Nara, Japan

  • Research Site

    Niigata, Japan

  • Research Site

    Numakunai, Japan

  • Research Site

    Okayama, Japan

  • Research Site

    Okinawa, Japan

  • Research Site

    Osaka, D8224C00001, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Ōita, Japan

  • Research Site

    Saitama, D8224C00001, Japan

  • Research Site

    Saitama, Japan

  • Research Site

    Shiga, D8224C00001, Japan

  • Research Site

    Shiga, Japan

  • Research Site

    Shimane, Japan

  • Research Site

    Shizuoka, D8224C00001, Japan

  • Research Site

    Shizuoka, Japan

  • Research Site

    Tokyo, D8224C00001, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Tottori, Japan

  • Research Site

    Toyama, Japan

  • Research Site

    Wakayama, D8224C00001, Japan

  • Research Site

    Wakayama, Japan

  • Research Site

    Yamagata, Japan

  • Research Site

    Yamaguchi, Japan

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA)